EP3737684B1 - 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases - Google Patents

2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases Download PDF

Info

Publication number
EP3737684B1
EP3737684B1 EP19700269.4A EP19700269A EP3737684B1 EP 3737684 B1 EP3737684 B1 EP 3737684B1 EP 19700269 A EP19700269 A EP 19700269A EP 3737684 B1 EP3737684 B1 EP 3737684B1
Authority
EP
European Patent Office
Prior art keywords
methyl
tetrahydro
pyrimidin
pyrazolo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19700269.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3737684A1 (en
Inventor
Sylvie FROIDEVAUX
Francis Hubler
Mark Murphy
Dorte Renneberg
Simon STAMM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Priority to SI201930400T priority Critical patent/SI3737684T1/sl
Priority to HRP20221449TT priority patent/HRP20221449T1/hr
Priority to RS20221138A priority patent/RS63806B1/sr
Publication of EP3737684A1 publication Critical patent/EP3737684A1/en
Application granted granted Critical
Publication of EP3737684B1 publication Critical patent/EP3737684B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to novel C5a receptor modulators of formula (I) and to such compounds for use as pharmaceuticals.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and their use as C5a receptor modulators, especially in the treatment of vasculitic diseases or disorders, inflammatory diseases or disorders involving intravascular microvesicle release, immune complex (IC) diseases or disorders, neurodegenerative diseases or disorders, complement related inflammatory diseases or disorders, bullous diseases or disorders, diseases or disorders related to ischemia and/or ischemic reperfusion injury, inflammatory bowel diseases or disorders, and autoimmune diseases or disorders; as well as in contact sensitivity or an inflammation caused by contact with artificial surfaces; increased leukocyte and platelet activation (and infiltration to tissues thereof); pathologic sequelae associated to an intoxication or an injury such as a trauma, an hemorrhage, a shock, or surgery including transplantation, such sequelae including multiple organ failure (MOF), septic shock, shock due
  • C5aR1 (CD88) is a seven transmembrane bound G protein coupled receptor (GPCR) belonging to the rhodopsin like family, the gene of which is located on chromosome 19. It couples to pertussis toxin sensitive Gialpha2, Gialpha3 or pertussis toxin insensitive Galpha16 and initiates several downstream signaling pathways.
  • GPCR G protein coupled receptor
  • C5aR1 is expressed on a number of immune cell types including monocytes, neutrophils, mast cells, basophils and eosinophils. In addition, it is expressed on many other cell types including hepatocytes, pulmonary and endothelial cells, microglia, neurons and renal glomerular cells.
  • C5aR There are a number of ligands described which bind to the C5aR. These include C5a, C5adesArg and C5a +1kDa.
  • C5a is a central effector molecule of the complement system which itself is a complex enzymatic cascade evolved to crucially complement the immune system against invading pathogens, however, a significant body of evidence shows that inadvertent complement activation leads to many acute inflammatory disorders and autoimmune diseases ( Ricklin, D., et al. (2010) "Complement: a key system for immune surveillance and homeostasis.” Nat Immunol 11(9): 785-797 ) and specifically C5a has been shown to be elevated in a number of these inflammatory and autoimmune disorders.
  • the complement system is activated through four pathways: The classical pathway, and the mannose binding lectin (MBL) pathway which is similar to the classical pathway except for the initial recognition and activation steps which recognize pathogens or antibody complexes.
  • the alternative pathway is activated by binding of spontaneously activated complement C3 protein (C3b fragment) to pathogen surface. These three pathways all lead to the eventual formation of C3 convertases, which is the point where the 3 pathways converge ( Guo, R. F. and P. A. Ward (2005) Annu Rev Immunol 23: 821-852 ). Subsequently C3 convertases lead to the formation of the anaphalatoxins C3a and C5a, together with other complement proteins required to produce the membrane attack complex.
  • a fourth pathway, the extrinsic pathway involves plasma proteases (eg. elastase, thrombin) which act directly on C3 or C5 leading to the subsequent production of C3a and C5a.
  • the anaphylatoxin C5a leads to the recruitment and activation of inflammatory cells of the innate and adaptive system, partly through the enhancement of cell adhesion molecule expression, the release of granule-based enzymes, delayed or enhanced apoptosis, phagocytosis, oxidative burst, histamine secretion and release and chemotaxis.
  • C5a represents one of the most potent inflammatory molecules produced during immune responses and because of its fundamental biology it is potentially implicated in a very wide range of pathologies ( Janeway's Immunobiology, 8th edition (2012), Kenneth Murphy, Garland Science, p. 48-72 ).
  • C5a is central to the immune system and as such is important in key aspects of inflammation and tissue injury.
  • C5a is central to the immune system and as such is important in key aspects of inflammation and tissue injury.
  • a C5a antagonist may be useful to treat vasculitic diseases such as ANCA associated vasculitis, leukoclastic vasculitis, Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, Henoch-Schonlein purpura, polyateritis nodosa, rapidly progressive glomerulonephritis (RPGN), cryoglobulinaemia, giant cell arteritis (GCA), Behcet's disease and Takayasu's arteritis (TAK).
  • vasculitic diseases such as ANCA associated vasculitis, leukoclastic vasculitis, Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, Henoch-Schonlein purpura, polyateritis nodosa, rapidly progressive glomerulonephritis (RPGN), cryoglobulinaemia, giant cell arteritis (GCA
  • C5a is generated when human blood makes contact with artificial surfaces, such as in cardiopulmonary bypass and hemodialysis procedures for instance on the artificial surface of the heart - lung machine in association with vascular surgery such as coronary artery bypass grafting or heart valve replacement or on surfaces of a kidney dialysis machine
  • artificial surfaces such as in cardiopulmonary bypass and hemodialysis procedures for instance on the artificial surface of the heart - lung machine in association with vascular surgery such as coronary artery bypass grafting or heart valve replacement or on surfaces of a kidney dialysis machine
  • C5aR antagonists could prove useful in preventing deleterious consequences of contact sensitivity and/or inflammation caused by contact with artificial surfaces.
  • it may be useful in treating inflammatory disorders involving intravascular microvesicle release such as for example thrombotic microangiopathy and sickle cell disease ( Zecher, D., et al. (2014) Arterioscler Thromb Vasc Biol 34(2): 313-320 ).
  • a C5aR antagonist could also prove useful in certain hemotological diseases which are associated with activation of coagulation and fibrinolytic systems, disseminated intravascular coagulation (DIC), pernicious anemia, warm and cold autoimmune hemolytic anemia (AIHA), anti- phospholipid syndrome and its associated complications, arterial and venous thrombosis, pregnancy complications such as recurrent miscarriage and fetal death, preeclampsia, placental insufficiency, fetal growth restriction, cervical remodeling and preterm birth, idiopathic thrombocytopenic purpura (ITP), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH) and allergic transfusion reactions.
  • DIC disseminated intravascular coagulation
  • AIHA warm and cold autoimmune hemolytic anemia
  • IHA autoimmune hemolytic anemia
  • INP atypical hemolytic uremic syndrome
  • PNH paroxysmal nocturnal hemoglobin
  • the C5-specific humanized antibody, eculizumab is approved for paroxysmal nocturnal hemoglobinuria and atypical haemolytic uraemic syndrome (aHUS) ( Wong EK, Kavanagh D, Transl Res. (2015) 165(2):306-20 ) and has been shown to be efficacious in renal transplant such as acute antibody-mediated kidney allograft rejection and cold agglutinin disease further supporting a potential role for C5aR antagonists in these diseases.
  • aHUS haemolytic uraemic syndrome
  • C5a In myocardial ischemia-reperfusion injury C5a has been described to have an important function. Complement depletion reduced myocardial infarct size in mice ( Weisman, H. F., T. et al. (1990) Science 249(4965): 146-151 ; De Hoog, V. C., et al. (2014) Cardiovasc Res 103(4): 521-529 ) and treatment with anti-C5a antibodies reduced injury in a rat model of hindlimb ischemia-reperfusion ( Bless, N. M., et al. (1999) Am J Physiol 276(1 Pt 1): L57-63 ).
  • Reperfusion injury during myocardial infarction was also markedly reduced in pigs that were re-treated with a monoclonal anti-C5a IgG ( Amsterdam, E. A., et al. (1995) Am J Physiol 268(1 Pt 2): H448-457 ).
  • a recombinant human C5aR antagonist reduces infarct size in a porcine model of surgical revascularization ( Riley, R. D., et al. (2000) J Thorac Cardiovasc Surg 120(2): 350-358 ) providing evidence for the utility of a C5aR antagonist in these diseases.
  • diseases related to ischemia / reperfusion injury such as those resulting from transplants, including solid organ transplant, where C5a has been shown to play an important role
  • C5aR antagonist could benefit from a C5aR antagonist as could related syndromes such as ischemic reperfusion injury, ischemic colitis and cardiac ischemia ( Mueller, M., et al. (2013) Immunobiology 218(9): 1131-1138 ).
  • C5aR modulators may be used preventatively in a patient at risk for myocardial infarction or thrombosis (i.e.
  • a patient who has one or more recognized risk factors for myocardial infarction or thrombosis such as, but not limited to, obesity, smoking, high blood pressure, hypercholesterolemia, previous or genetic history of myocardial infarction or thrombosis) in order reduce the risk of myocardial infarction or thrombosis.
  • risk factors for myocardial infarction or thrombosis such as, but not limited to, obesity, smoking, high blood pressure, hypercholesterolemia, previous or genetic history of myocardial infarction or thrombosis
  • C5a causes increased capillary permeability and edema, leukocyte and platelet activation and infiltration to tissues, as well as bronchoconstriction ( Sarma, J. V. and P. A. Ward (2012) Cell Health Cytoskelet 4: 73-82 ; Czermak, B. J., et al. (1998) J Leukoc Biol 64(1): 40-48 ).
  • Administration of an anti-C5a monoclonal antibody was shown to reduce cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction ( Tofukuji, M., et al. (1998) J Thorac Cardiovasc Surg 116(6): 1060-1068 ).
  • ARDS acute respiratory distress syndrome
  • COPD Chronic Obstructive Pulmonary Disorder
  • MOF multiple organ failure
  • C5a increases monocyte production of two important proinflammatory cytokines TNF- ⁇ and IL-I which contribute to pathology in these diseases.
  • C5a has also been shown to play an important role in the development of tissue injury, and particularly pulmonary injury, in animal models of septic shock ( Smedegard, G., et al. (1989) Am J Pathol 135(3): 489-497 ; Unnewehr, H., et al. (2013) J Immunol 190(8): 4215-4225 ).
  • anti-C5a antibodies administered to the animals before treatment with endotoxin or E.
  • anti-C5a antibodies were shown to inhibit apoptosis of thymocytes ( Guo, R. F., et al. (2000) J Clin Invest 106(10): 1271-1280 ).
  • Anti-C5a antibodies were also protective in a cobra venom factor model of lung injury in rats, and in immune complex-induced lung injury ( Mulligan, M. S., et al. (1996) J Clin Invest 98(2): 503-512 ).
  • the importance of C5a in immune complex-mediated lung injury was also shown in mouse ( Bozic, C. R., et al. (1996) Science 273(5282): 1722-1725 ).
  • a C5aR antagonist could be of benefit in many inflammatory disorders and related conditions including neutropenia, sepsis, septic shock, stroke, inflammation associated with severe burns ( Hoesel, L. M., et al. (2007) J Immunol 178(12): 7902-7910 ), osteoarthritis ( Yuan, G., et al. (2003) Chin Med J (Engl) 116(9): 1408-1412 ), as well as acute (adult) respiratory distress syndrome (ARDS), chronic pulmonary obstructive disorder (COPD), bronchial asthma ( Pandey, M. K.
  • C5aR antagonists may be beneficial in treating pathologic sequelae associated with insulin-dependent diabetes mellitus such as diabetic kidney disease ( Li, L., et al. (2015) Metabolism 64(5): 597-610 ), diabetic retinopathy ( Cheng, L., et al. (2013). Invest Ophthalmol Vis Sci 54(13): 8191-8198 ), lupus nephropathy ( Bao, L., et al.
  • C5aR antagonists substantially reduced ovalbumin (OVA)-induced total cell (60%), neutrophil (66%) and eosinophil (65%) influxes in lavage fluid sampling suggesting that C5aR blockage might represent a novel therapeutic agent for reducing asthmatic outcomes ( Staab, E. B., et al. (2014) Int Immunopharmacol 21(2): 293-300 ).
  • the complement system and in particular C5a contribute to the development of many bullous diseases among other things through activation of innate cells including mast cells and neutrophils (e.g. bullous pemphigoid, bullous acquisita, pemphigus foliaceus and pemphigus vulgaris).
  • innate cells including mast cells and neutrophils
  • neutrophils e.g. bullous pemphigoid, bullous acquisita, pemphigus foliaceus and pemphigus vulgaris.
  • the detachment of epidermal basal keratinocytes from the underlying basement membrane is thought to be caused by autoantibodies to keratinocytes at the cutaneous basement membrane leading to blisters and a high influx of neutrophils in both the upper dermal layers and within the blister cavities.
  • Complement is believed to be important in inflammatory bowel disease (IBD) pathology and the C5aR is found to be expressed in the epithelial cells of the colon.
  • IBD inflammatory bowel disease
  • C5aR is found to be expressed in the epithelial cells of the colon.
  • pharmacological inhibition of C5a activity by PMX205 a peptidic C5aR antagonist is efficacious in preventing DSS-induced colitis, providing further evidence that targeting CD88 in patients with IBD irritable bowel syndrome, ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBD) ( Johswich, K., et al.
  • C5aR expression is upregulated on reactive astrocytes, microglia, and endothelial cells in an inflamed human central nervous system ( O'Barr, S. A., et al. (2001) J Immunol 166(6): 4154-4162 ; Gasque, P., et al. (1997) Am J Pathol 150(1): 31-41 ) and C5a has been reported to be involved in the pathogenesis of many neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) ( Mantovani, S., et al.
  • ALS amyotrophic lateral sclerosis
  • C5aR antagonists provided herein may be to treat ALS, Alzheimer's disease, multiple sclerosis, Guillain-Barre syndrome, Parkinson's disease, Huntington's disease and also cognitive function decline associated with cardiopulmonary bypass surgery and related procedures in addition to central nervous system involvement in diseases such as SLE, Sjögren's syndrome and associated immunological profiles.
  • IC Immunoglobulin G-containing immune complex
  • SLE systemic lupus erthyematosus
  • cryoglobulinemia rheumatoid arthritis
  • Sjögren's syndrome Lawley, T. J., et al. (1979) J Immunol 123(3): 1382-1387
  • Goodpasture syndrome antiglomerular basement antibody disease
  • inhibitors of C5aR could be useful to treat IC diseases including the autoimmune diseases rheumatoid arthritis ( Jose, P. J., et al. (1990) Ann Rheum Dis 49(10): 747-752 ; Grant, E. P., et al. (2002) J Exp Med 196(11): 1461-1471 ; Yuan, G., et al.
  • C5a is present in psoriatic plaques and C5aR expression has also been reported in psoriasis where T cells, neutrophils mast cells and dendritic cells are involved in pathogenesis of the disease and are chemotactic to C5a ( Diani, M., G. Altomare and E. Reali (2015) Autoimmun Rev 14(4): 286-292 ).
  • Neutrophil accumulation under the stratum corneum is observed in the highly inflamed areas of psoriatic plaques, and psoriatic lesion (scale) extracts contain highly elevated levels of C5a and exhibit potent chemotactic activity towards neutrophils, an effect that can be inhibited by addition of a C5a antibody.
  • C5aR antagonists may be of benefit in treating psoriasis.
  • complement has been implicated in the pathogenesis of glaucoma ( Howell et al.
  • C5a and C5aR are believed to be clinically implicated in vasculitic diseases or disorders, inflammatory diseases or disorders involving intravascular microvesicle release, immune complex (IC) diseases or disorders, neurodegenerative diseases or disorders, complement related inflammatory diseases or disorders, bullous diseases or disorders, diseases or disorders related to ischemia and/or ischemic reperfusion injury, inflammatory bowel diseases or disorders, and autoimmune diseases or disorders; as well as in contact sensitivity or an inflammation caused by contact with artificial surfaces; increased leukocyte and platelet activation (and infiltration to tissues thereof); pathologic sequelae associated to an intoxication or an injury such as a trauma, an hemorrhage, a shock, or surgery including transplantation, including multiple organ failure (MOF), septic shock, shock due to intoxication, or acute lung inflammatory injury; pathologic sequelae associated with insulin-dependent diabetes mellitus; myocardial infarction or thrombosis; edema or an increased capillary permeability; reduction of coronary end
  • C5aR C5a receptor
  • WO2006/042102 discloses pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds that act as modulators of mammalian complement C5a receptors.
  • WO2014/134426 discloses methods of treating PI3K ⁇ related disorders using pyrazolopyrimidine derivatives.
  • the present invention provides cyclic urea derivatives of formula (I) which are modulators of the C5a receptor, and, thus, may be useful for the prevention or treatment of diseases which respond to the C5a receptor.
  • the compounds of formula (I) may contain one or more further stereogenic or asymmetric centers, such as one or more additional asymmetric carbon atoms.
  • the compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
  • enriched when used in the context of stereoisomers, is to be understood in the context of the present invention to mean that the respective stereoisomer is present in a ratio of at least 70:30, especially of at least 90:10 (i.e., in a purity of at least 70% by weight, especially of at least 90% by weight), with regard to the respective other stereoisomer / the entirety of the respective other stereoisomers.
  • essentially pure when used in the context of stereoisomers, is to be understood in the context of the present invention to mean that the respective stereoisomer is present in a purity of at least 95% by weight, especially of at least 99% by weight, with regard to the respective other stereoisomer / the entirety of the respective other stereoisomers.
  • the compounds of formula (I) may contain tautomeric forms. Such tautomeric forms are encompassed in the scope of the present invention.
  • the present compounds may contain heterocyclic aromatic rings containing unsubstituted ring nitrogen atoms having a free valency such as triazolyl, or pyrazolyl, such rings may be present in tautomeric forms.
  • the group pyrazol-3-yl represents the tautomeric forms 1 H -pyrazol-3-yl and 2 H -pyrazol-3-yl.
  • R 5 , R 7 , or R 8 represents hydrogen
  • the corresponding compounds of formula (I) may be present in form of tautomers, e.g.
  • the compound 6-[1-(2-Fluoro-6-methyl-phenyl)-piperidin-4-yl]-4-(2-trifluoromethyl-benzyl)-2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one is a tautomeric form of 6-[1-(2-Fluoro-6-methyl-phenyl)-piperidin-4-yl]-4-(2-trifluoromethyl-benzyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one, both names representing the same chemical entity.
  • the compound 5-[1-(2-Fluoro-6-methyl-phenyl)-piperidin-4-yl]-7-(2-trifluoromethyl-benzyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-6-one is a tautomeric form of 5-(1-(2-fluoro-6-methylphenyl)piperidin-4-yl)-7-(2-(trifluoromethyl)benzyl)-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-d]pyrimidin-6-one, both names representing the same chemical entity.
  • the present invention also includes isotopically labelled, especially 2 H (deuterium) labelled compounds of formula (I), which compounds are identical to the compounds of formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • Isotopically labelled, especially 2 H (deuterium) labelled compounds of formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2 H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life and/or reduced dosage requirements, and/or may lead to a modified metabolism pathway, resulting e.g. in an improved safety profile.
  • the compounds of formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled at all. Isotopically labelled compounds of formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
  • Deuterated groups are denominated as follows: for example the group (1,1,2,2,2- 2 H 5 -ethyl) denominates the residue
  • a bond drawn as a dotted line shows the point of attachment of the radical drawn.
  • the radical drawn below is a 2-fluoro-6-methyl-phenyl group.
  • salts refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects.
  • Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound.
  • Handbook of Pharmaceutical Salts. Properties, Selection and Use P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008 ; and " Pharmaceutical Salts and Co-crystals", Johan Wouters and Luc Qucha (Eds.), RSC Publishing, 2012 .
  • a saturated acyclic or cyclic group contains a heteroatom and/or is attached to a heteroatom that is part of the rest of the molecule and/or is substituted by a substituent that is attached through a heteroatom
  • such heteroatoms are preferably distant from each other by at least two carbon atoms.
  • halogen means fluorine, chlorine, bromine, or iodine, preferably fluorine or chlorine.
  • alkyl refers to a saturated straight or branched chain hydrocarbon group containing one to four carbon atoms.
  • (C x-y )alkyl refers to an alkyl group as defined before, containing x to y carbon atoms.
  • a (C 1-4 )alkyl group contains from one to four carbon atoms.
  • Examples of (C 1-4 )alkyl are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl and tert.-butyl.
  • propyl or butyl it is meant to be n-propyl, respectively n-butyl.
  • a group is referred to as (C 0-y )alkyl group, such group is absent and any free valency of the point of attachment is filled with hydrogen, or it contains 1 up to y carbon atoms as set out before.
  • Examples of (C 1-4 )alkyl as used for substituents of R 1 are methyl and isopropyl, and in addition ethyl.
  • Examples of (C 1-4 )alkyl as used for substituents of R 2 are methyl and isopropyl.
  • An example of (C 1-4 )alkyl as used for R 3 is methyl.
  • (C 1-4 )alkyl as used for R 4 is methyl.
  • Examples of (C 1-4 )alkyl as used for R 5 and R 6 independently are methyl, ethyl, isopropyl, isobutyl and tert-butyl; especially methyl.
  • An example of (C 1-4 )alkyl as used for R 7 and R 8 is methyl.
  • Examples of (C 1-4 )alkyl as used for R B are methyl, ethyl, isopropyl, and isobutyl.
  • -(C x-y )alkylene- refers to bivalently bound alkyl group as defined before containing x to y carbon atoms.
  • the points of attachment of a -(C 1-y )alkylene group are in 1,1-diyl, in 1,2-diyl, or in 1,3-diyl arrangement.
  • the points of attachment of a -(C 2-y )alkylene group are in 1,2-diyl or in 1,3-diyl arrangement.
  • a -(C 0 )alkylene- group is absent and refers to a direct bond, thus, the term -(C 0-4 )alkylene refers to a direct bond, or -(C 1-4 )alkylene.
  • An example of -(C 1-4 )alkylene as used for the linker X B (respectively, for the linker X B1 and X B2 ) is methylene.
  • Alkylene-oxy linker groups -(C 1-3 )alkylene-O- as used for example in the substituents (C 3-6 )cycloalkyl- X 21 - are to be read from left to right, i.e. they refer to the respective (C 3-6 )cycloalkyl-(C 1-3 )alkylene-O- groups.
  • An example for (C 3-6 )cycloalkyl- X 21 - wherein X 21 is -(C 1-3 )alkylene-O- is cyclopropyl-methoxy.
  • R 21a R 21b N-(C 2-3 )alkylene-O- is dimethylamino-ethoxy.
  • alkynyl refers to a straight or branched hydrocarbon chain containing two to five carbon atoms and one carbon-carbon triple bond.
  • (C x-y )alkynyl refers to an alkynyl group as defined before containing x to y carbon atoms.
  • a (C 2-5 )alkynyl group contains from two to five carbon atoms.
  • An example of an alkynyl group is 1,1-dimethyl-prop-2-ynyl.
  • alkoxy refers to an alkyl-O- group wherein the alkyl group is as defined before.
  • (C x-y )alkoxy (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms.
  • a (C 1-4 )alkoxy group means a group of the formula (C 1-4 )alkyl-O- in which the term "(C 1-4 )alkyl” has the previously given significance.
  • alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy.
  • An example of (C 1-4 )alkoxy as used for substituents of R 1 is methoxy.
  • Examples of (C 1-4 )alkoxy as used for substituents of R 2 are methoxy, ethoxy, isopropoxy.
  • Examples of (C 1-4 )alkoxy as used for R 5 being attached to (C 1-4 )alkyl are methoxy and ethoxy.
  • fluoroalkyl refers to an alkyl group as defined before containing one to four carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine.
  • (C x-y )fluoroalkyl refers to a fluoroalkyl group as defined before containing x to y carbon atoms.
  • a (C 1-3 )fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine.
  • fluoroalkyl groups include trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2-difluoropropyl, 2,2-difluoro-1-methyl-ethyl, 2-fluoropropyl, 2-fluoro-2-methyl-propyl.
  • Examples of (C 1-4 )fluoroalkyl as used for substituents of R 1 are trifluoromethyl, and, in addition, difluoromethyl.
  • An example of (C 1-4 )fluoroalkyl as used for substituents of R 2 is trifluoromethyl.
  • Examples of (C 2-4 )fluoroalkyl as used for R 5 are 2,2-difluoro-ethyl, 2,2-difluoro-propyl, 2,2-difluoro-1-methyl-ethyl, 2-fluoropropyl, and 2-fluoro-2-methyl-propyl.
  • Examples of (C 2-4 )fluoroalkyl as used for R 7 are 2-fluoro-2-methyl-propyl and 2,2-difluoro-propyl.
  • Examples of (C 2-4 )fluoroalkyl as used for R B are 2-fluoroethyl, and 2,2-difluoroethyl.
  • fluoroalkoxy refers to an alkoxy group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine.
  • (C x-y )fluoroalkoxy (x and y each being an integer) refers to a fluoroalkoxy group as defined before containing x to y carbon atoms.
  • a (C 1-3 )fluoroalkoxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine.
  • fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy.
  • An example of (C 1-4 )fluoroalkoxy as used for substituents of R 1 is trifluoromethoxy.
  • An example of (C 1-4 ) fluoroalkoxy as used for substituents of R 2 is trifluoromethoxy.
  • cyano refers to a group -CN.
  • cyano-(C 1-2 )alkoxy is to be read from left to right, i.e. it refers to the respective cyano-(C 1-2 )alkylene-O-group.
  • An example for cyano-(C 1-2 )alkoxy is cyano-methoxy.
  • cycloalkyl refers to a saturated monocyclic hydrocarbon ring containing three to six carbon atoms.
  • (C x-y )cycloalkyl refers to a cycloalkyl group as defined before containing x to y carbon atoms.
  • a (C 3-6 )cycloalkyl group contains from three to six carbon atoms.
  • Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Preferred are cyclopropyl and cyclobutyl; especially cyclopropyl.
  • An example of (C 3-6 )cycloalkyl as used for substituents of R 1 is cyclopropyl.
  • An example of (C 3-6 )cycloalkyl as used for substituents of R 2 is cyclopropyl.
  • Examples of (C 3-6 )cycloalkyl as used for R 5 being attached to (C 0-4 )alkylene- are cyclopropyl, cyclopentyl and cyclohexyl.
  • An example of (C 3-6 )cycloalkyl as used for R 8 is cyclopropyl.
  • (C 3-6 )cycloalkyl-O- as used for example in the substituents (C 3-6 )cycloalkyl- X 21 - wherein X 21 is -0- relates to (C 3-6 )cycloalkyl as defined above, attached via an ⁇ O- linker.
  • Examples of (C 3-6 )cycloalkyl-O- as used for substituents of R 2 are cyclopropyl-oxy and cyclobutyl-oxy.
  • cycloalkyl optionally containing one ring oxygen atom refers to a cycloalkyl group as defined before.
  • one ring carbon atom of said cycloalkyl may be replaced by an oxygen atom.
  • groups are especially cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; as well as oxygen containing groups such as oxetanyl, tetrahydrofuranyl, and tetrahydro-2H-pyranyl.
  • Examples of (C 3-6 )cycloalkyl- X 21 - groups wherein "the (C 3-6 )cycloalkyl optionally contains one ring oxygen atom" as used for substituents of R 2 are cyclopropyl, cyclopropyl-oxy, cyclobutyl-oxy, oxetan-3-yl-oxy, cyclopropyl-methoxy, tetrahydropyran-4-yl-oxy, especially oxetan-3-yl-oxy.
  • ring C An example of such group as used for ring C is oxetan-3-yl; in particular oxetan-3-yl, 3-methyl-oxetan-3-yl, 3-trifluoromethyl-oxetan-3-yl.
  • heterocyclyl used alone or in combination, and if not explicitly defined in a more narrow way, refers to a saturated monocyclic hydrocarbon ring containing one to three (especially one) ring heteroatoms independently selected from nitrogen, sulfur, and oxygen.
  • (C x-y )heterocyclyl refers to such a heterocyclyl group containing x to y ring atoms.
  • Heterocyclyl groups are unsubstituted or substituted as explicitly defined; wherein in case a ring nitrogen atom having a free valency is present, such ring nitrogen atom may be substituted as explicitly defined, in addition to further (optional) substituents of such heterocycle.
  • Oxo substituents are especially attached to a ring carbon atom in alpha position to a ring nitrogen (thus forming together with the nitrogen an amide group, or, in case a ring oxygen is additionally adjacent, a carbamate group, or, in case second ring nitrogen is additionally adjacent, a urea group); or two oxo substituents are substituents of a ring sulfur ring atom (thus forming an -SO 2 - group).
  • Heterocyclyl groups as used for the group ring B are attached to rest of the molecule (i.e.
  • X B at a ring carbon atom, comprise one substituted ring nitrogen atom NR B wherein R B is as explicitly defined, and are, in addition to R B , optionally substituted as explicitly defined.
  • heterocyclyl groups as used for the group ring B are oxetanyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, azetidinyl, pyrrolidinyl, piperidinyl, and morpholinyl; in particular oxetan-3-yl, azetidin-2-yl, azetidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, and piperidin-4-yl.
  • R N1 R N2 N- wherein R N1 and R N2 together with the nitrogen atom form a 4- to 6-membered saturated ring optionally containing one further ring heteroatom selected from O and N are azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, and morpholin-4-yl; in particular 3-methoxy-azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-methyl-piperazin-1-yl, and morpholin-4-yl.
  • ring A representing "a saturated 4- to 7-membered mono-cyclic carbocyclic ring containing the ring nitrogen atom to which R 1 is attached" are azetidin-1,3-diyl, pyrrolidin-1,3-diyl, piperidin-1,4-diyl, piperidin-1,3-yl, and azepan-1,4-diyl; as well as the substituted groups 3-methyl-pyrrolidin-1,3-diyl, and 4-methyl-piperidin-1,4-diyl.
  • the substituent phenyl as used for R 1 independently is mono-, di- or tri-substituted, notably mono-, or di-substituted, especially mono- or di-substituted wherein at least one substituent is attached in ortho position with regard to the point of attachment of the rest of the molecule.
  • Examples are mono-substituted phenyl groups such as 2-methoxy-phenyl; and di-substituted phenyl groups such as 2-chloro-6-methyl-phenyl, 2-fluoro-6-methyl-phenyl, 2,6-dimethyl-phenyl, 2-methoxy-6-methyl-phenyl, 2-fluoro-6-cyano-phenyl, 2-fluoro-6-trifluoromethyl-phenyl, 2-fluoro-6-trifluoromethoxy-phenyl, and, in addition, 2,6-difluorophenyl, 2-chloro-6-fluoro-phenyl, 2-bromo-6-fluoro-phenyl, 2-fluoro-6-ethyl-phenyl, 2-fluoro-6-difluoromethyl-phenyl, and 2-fluoro-6-cyclopropyl-phenyl.
  • the substituent phenyl as used for R 2 is mono-, di- or tri-substituted, notably mono-, or di-substituted, especially mono- or di-substituted wherein at least one substituent is attached in ortho position with regard to the point of attachment of the rest of the molecule.
  • Examples are mono-substituted phenyl group such as 2-chloro-phenyl, 2-cyclopropyl-phenyl, 2-isopropyl-phenyl, 2-ethoxy-phenyl, 2-trifluoromethyl-phenyl, 2-isopropoxy-phenyl, 2-cyclopropoxy-phenyl, 2-(oxetan-3-yloxy)-phenyl, 2-cyclopropylmethoxy-phenyl, 2-trifluoromethoxy-phenyl; di-substituted phenyl groups such as 2-fluoro-6-trifluoromethyl-phenyl and 2-bromo-6-trifluoromethyl-phenyl; and tri-substituted phenyl groups such as 2,4-difluoro-6-isopropoxy-phenyl.
  • heteroaryl used alone or in combination, means a 5- to 6-membered monocyclic aromatic ring containing one to a maximum of three heteroatoms, each independently selected from oxygen, nitrogen and sulfur.
  • heteroaryl groups are 5-membered heteroaryl such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl; and 6-membered heteroaryl such as pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl.
  • heteroaryl groups are unsubstituted or substituted as explicitly defined.
  • 5- or 6-membered heteroaryl group is substituted in ortho-position with regard to the point of attachment of the rest of the molecule, it is understood that such substituent is attached in direct neighbourhood with regard to the point of attachment of the rest of the molecule, i.e. in a relative 1,2-arrangement.
  • heteroaryl as used for the substituent R 1 are notably 6-membered heteroaryl containing one or two nitrogen atoms, or 5-membered heteroaryl containing one or two ring nitrogen atoms and optionally one further heteroatom selected from nitrogen, oxygen or sulfur; in particular 4-chloro-2,5-dimethyl-2H-pyrazol-3-yl, 2,5-dimethyl-4-cyano-pyrazol-3-yl, 3-fluoro-pyridin-2-yl, 3-methoxy-pyridin-2-yl, 2-methoxy-4-methyl-pyridin-3-yl, 2-fluoro-4-methyl-pyridin-3-yl, 2-methyl-4-fluoro-pyridin-3-yl, 2-cyano-4-methyl-pyridin-3-yl, 2,4-dimethoxy-pyridin-3-yl, 4-methoxy-6-methyl-pyrimidin-5-yl, 4,6-dimethoxy-pyrimidin-5-yl, and, in addition, 2-methoxy
  • heteroaryl as used for the substituent R 2 are especially 6-membered heteroaryl containing one or two nitrogen atoms; or 5-membered heteroaryl containing one or two ring nitrogen atoms and one further heteroatom independently selected from nitrogen, oxygen or sulfur; in particular 4-isopropyl-pyrimidin-5-yl, 3-trifluoromethyl-pyrazin-2-yl, 3-trifluoromethyl-pyridin-2-yl, 6-methyl-3-trifluoromethyl-pyridin-2-yl, 6-deutero-3-trifluoromethyl-pyridin-2-yl, 6-chloro-3-trifluoromethyl-pyridin-2-yl, 6-fluoro-3-trifluoromethyl-pyridin-2-yl, 6-methylamino-3-trifluoromethyl-pyridin-2-yl, 6-methoxy-3-trifluoromethyl-pyridin-2-yl, 6-dimethylamino-3-trifluoromethyl-pyridin-2-yl, 4-
  • heteroaryl as used for the substituent ring D are notably 5-membered heteroaryl containing one or two nitrogen atoms and optionally one further heteroatom independently selected from nitrogen, oxygen or sulfur, such as especially oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl; in particular 5-methyl-[1,3,4]-oxadiazol-2-yl, 5-isopropyl-[1,3,4]-oxadiazol-2-yl and 5-trifluoromethyl-[1,3,4]-oxadiazol-2-yl.
  • ring A (wherein especially ring A is piperidin-1,4-diyl) is substituted with R 1 and carries no further substituent (i.e. R A in the fragment above is absent and the free valency of the respective ring carbon atom is saturated with hydrogen)].
  • FIG. 3 Another embodiment relates to compounds according to embodiments 1) or 2), wherein ring A is substituted with R 1 and carries no further substituent [i.e. ring A represents a fragment:
  • Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein Y represents N R 5 ; one of X and Z represents N, and the other of X and Z represents N or CH.
  • this embodiment encompasses ring groups wherein
  • Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein
  • Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein
  • Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein
  • Another embodiment relates to compounds according to any one of embodiments 1) to 3), wherein
  • Another embodiment relates to compounds according to any one of embodiments 1) to 8), wherein R 1 represents
  • Another embodiment relates to compounds according to any one of embodiments 1) to 8), wherein R 1 represents
  • Another embodiment relates to compounds according to any one of embodiments 1) to 8), wherein R 1 represents phenyl which is mono-, or di-substituted; wherein at least one substituent is attached in ortho position with regard to the point of attachment of the rest of the molecule;
  • R 1 is 2-chloro-6-methyl-phenyl, 2-fluoro-6-methyl-phenyl, 2,6-dimethyl-phenyl, 2-methoxy-6-methyl-phenyl, 2-fluoro-6-cyano-phenyl, 2-fluoro-6-trifluoromethyl-phenyl, 2-fluoro-6-trifluoromethoxy-phenyl, 4-chloro-2,5-dimethyl-2H-pyrazol-3-yl, 2,5-dimethyl-4-cyano-pyrazol-3-yl, 3-fluoro-pyridin-2-yl, 3-methoxy-pyridin-2-yl, 2-methoxy-4-methyl-pyridin-3-yl, 2-fluoro-4-methyl-pyridin-3-yl, 2-methyl-4-fluoro-pyridin-3-yl 2-cyano-4-methyl-pyridin-3-yl, 2,4-dimethoxy-pyr
  • R 2 represents phenyl, 5-membered heteroaryl (notably 5-membered heteroaryl containing one or two ring nitrogen atoms and one further heteroatom independently selected from nitrogen, oxygen or sulfur; especially thiazolyl); or 6-membered heteroaryl (notably 6-membered heteroaryl containing one or two nitrogen atoms; especially pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl); wherein said phenyl, 5-membered heteroaryl, or 6-membered heteroaryl, independently is mono-, or di-, or tri-substituted (notably mono-, or di-substituted, especially mono-, or di-substituted wherein at least one substituent is attached in ortho position with regard to the point of attachment of the rest of the molecule), wherein the substituents are independently selected from
  • Another embodiment relates to compounds according to any one of embodiments 1) to 15), wherein R 2 represents
  • R 2 is 2-chloro-phenyl, 2-cyclopropyl-phenyl, 2-isopropyl-phenyl, 2-ethoxy-phenyl, 2-trifluoromethyl-phenyl, 2-isopropoxy-phenyl, 2-cyclopropoxy-phenyl, 2-(oxetan-3-yloxy)-phenyl, 2-cyclopropylmethoxy-phenyl, 2-fluoro-6-trifluoromethyl-phenyl, 2-bromo-6-trifluoromethyl-phenyl, 2-trifluoromethoxy-phenyl, 2,4-difluoro-6-isopropoxy-phenyl, 4-isopropyl-pyrimid-5-yl, 3-trifluoromethyl-pyrazin-2-yl, 3-trifluoromethyl-pyridin-2-yl, 6-methyl-3-trifluoromethyl-pyridin-2-yl, 6-ch
  • Another embodiment relates to compounds according to any one of embodiments 1) to 19), wherein R 3 represents hydrogen, or methyl (especially hydrogen).
  • Another embodiment relates to compounds according to any one of embodiments 1) to 20), wherein R 4 represents hydrogen or methyl (especially hydrogen).
  • Another embodiment relates to compounds according to any one of embodiments 1) to 21), wherein R 5 represents
  • Another embodiment relates to compounds according to any one of embodiments 1) to 21), wherein R 5 represents
  • R 5 represents (C 2-4 )fluoroalkyl (especially 2,2-difluoro-ethyl, 2,2-difluoro-propyl, 2,2-difluoro-1-methyl-ethyl, 2-fluoropropyl, 2-fluoro-2-methyl-propyl; in particular 2,2-difluoro-propyl).
  • Another embodiment relates to compounds according to any one of embodiments 1) to 21), wherein R 5 represents (C 2-5 )alkynyl (especially 1,1-dimethyl-prop-2-ynyl).
  • R 5 represents (C 2-4 )alkenyl (especially isopropenyl, 2-methyl-propenyl, or 2-methyl-allyl).
  • R 5 represents R N3 R N4 N-C(O)-(C 0-4 )alkylene-, wherein R N3 and R N4 independently are hydrogen or (C 1-4 )alky (especially (CH 3 ) 2 N-C(O)-, (isobutyl)(methyl)N-C(O)-, H 2 N-C(O)CH 2 -, H 2 N-C(O)-CH(CH 3 )-, (CH 3 ) 2 N-C(O)-CH 2 - or H 2 N-C(O)-C(CH 3 ) 2 -).
  • R 5 represents (C 1-4 )alkoxy-C(O)-(C 0-4 )alkylene-; (C 1-4 )alkoxy-C(O)-(C 2-4 )alkylene-, wherein the (C 2-4 )alkylene is mono-substituted by R N5 R N6 N-, wherein R N5 and R N6 independently are hydrogen or (C 1-4 )alkyl (especially (CH 3 ) 2 CH-O-C(O)-, (CH 3 )2CHCH 2 -O-C(O)-, CH 3 O-C(O)-CH 2 -, H 3 CO-C(O)-C(CH 3 ) 2 -, H 3 CO-C(O)-CH(CH 3 )CH 2 - and CH 3 O-C(O)-CH[N(CH 3 ) 2 ]-CH 2 ).
  • R 5 represents (C 1-4 )alkoxy-C(O)-NH-(C 2-4 )alkylene-, wherein the (C 2-4 )alkylene- is optionally substituted by one to three halogen (especially fluoro).
  • substituents for such a substituent are 2-(tert-butoxycarbonylamino)-ethyl, and 2,2,2-trifluoro-(1-(tert-butyloxycarbonyl-amino)-1-(methyl)-ethan-1-yl).
  • R 5 represents (C 3-6 )cycloalkyl-(C 0-4 )alkylene-, wherein the cycloalkyl is optionally substituted by one or two substituents independently selected from fluoro, (C 1-4 )alkyl, nitro, or (C 1-4 )alkoxy-C(O)-NH- (especially fluoro, methyl)
  • substituents independently selected from fluoro, (C 1-4 )alkyl, nitro, or (C 1-4 )alkoxy-C(O)-NH- (especially fluoro, methyl)
  • examples for (C 3-6 )cycloalkyl-(C 0-4 )alkylene- are especially cyclopropyl, cyclopropylmethyl, 1-fluoro-cyclopropyl-methyl, 1-methyl-cyclopropyl-methyl, 2,2-difluoro-cyclopropylmethyl; in particular cyclopropyl].
  • R 5 represents ring B - X B -; wherein X B is a direct bond, or (C 1-4 )alkylene- (especially methylene); and wherein ring B is a 4- to 6-membered saturated heterocyclyl containing one or two ring heteratom independently selected from O, S, and N R B , wherein said ring B is attached to X B at a ring carbon atom (especially oxetan-3-yl, azetidin-2-yl, azetidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl);
  • Another embodiment relates to compounds according to any one of embodiments 1) to 21), wherein R 5 represents hydrogen.
  • Another embodiment relates to compounds according to any one of embodiments 1) to 21), wherein R 5 represents (C 1-4 )alkyl (in particular methyl).
  • Another embodiment relates to compounds according to any one of embodiments 1) to 35), wherein R 6 represents hydrogen; (C 1-4 )alkyl; or (C 1-4 )fluoroalkyl (especially R 6 represents hydrogen or methyl).
  • R 7 represents hydrogen, (C 1-4 )alkyl (especially methyl), or (CH 3 ) 3 Si-CH 2 CH 2 OCH 2 -.
  • the invention thus, especially relates to compounds of the formula (I) as defined in embodiment 1), and to such compounds further limited by the characteristics of any one of embodiments 2) to 38), under consideration of their respective dependencies; to pharmaceutically acceptable salts thereof; and to the use of such compounds as medicaments especially for use in the prevention / prophylaxis or treatment of diseases and disorders related to pathogenic events associated with elevated levels of C5a and/or with C5aR activation.
  • a second aspect of the invention relates to compounds of the formula (I) according to embodiment 1), which are also compounds of the formula (II) wherein
  • Another embodiment relates to compounds of formula (II) according to embodiment 40), wherein
  • a third aspect of the invention relates to compounds of the formula (I) according to embodiment 1), which are also compounds of the formula (III) wherein
  • a further aspect of the invention relates to compounds of the formula (III) according to embodiment 42) or 43), which are also compounds of the formula (IV); wherein the absolute configuration is as depicted in formula (IV):
  • Embodiment 44 further relates to the compounds of formula (I) according to any one of embodiments 1) to 39), wherein, in case R 4 is different from hydrogen, the absolute configuration is, mutatis mutandis, as depicted in formula (IV).
  • Another embodiment relates to compounds according to embodiment 1) which are selected from the following compounds:
  • the compounds of formula (I) according to embodiments 1) to 50) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation).
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins ]) by bringing the described compounds of formula (I) or (II), or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • the present invention also relates to a a compound of formula (I) as defined in any one of embodiments 1) to 50) for use in a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of such a compound .
  • the administered amount is comprised between 1 mg and 1000 mg per day, particularly between 5 mg and 500 mg per day, more particularly between 25 mg and 400 mg per day, especially between 50 mg and 200 mg per day.
  • the term "about” placed before a numerical value "X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X.
  • the term “about” placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C.
  • the compounds of formula (I) as defined in any one of embodiments 1) to 50) are useful for the prevention / prophylaxis or treatment of diseases and disorders related to pathogenic events associated with elevated levels of C5a and/or with C5aR activation.
  • Such diseases and disorders related to pathogenic events associated with elevated levels of C5a and/or with C5aR activation are especially:
  • the present compounds may in addition be useful for
  • Vasculitic diseases or disorders include especially vasculitis, ANCA associated vasculitis and glomerulonephritis (GN, especially rapidly progressive GN) associated with ANCA associated vasculitis, leukoclastic vasculitis, granulomatosis with polyangiitis (GPA, also referred to as Wegener's granulomatosis), microscopic polyangiitis, Churg-Strauss syndrome, Henoch-Schonlein purpura, polyateritis nodosa, cryoglobulinaemia, giant cell arteritis (GCA), Behcet's disease, and Takayasu's arteritis (TAK).
  • Inflammatory diseases or disorders involving intravascular microvesicle release include especially thrombotic microangiopathy, and sickle cell disease.
  • Immune complex (IC) diseases or disorders include especially cryoglobulinemia, Sjögren's syndrome (and associated immunological profiles), Goodpasture syndrome (antiglomerular basement antibody disease) and glomerulonephritis (GN, especially rapidly progressive GN) or pulmonary hemorrhage associated with Goodpasture syndrome, and hypersensitivity;
  • Neurodegenerative diseases and disorders include especially amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, Guillain-Barre syndrome, neuropathy, , and cognitive function decline associated with cardiopulmonary bypass surgery and related procedures.
  • ALS amyotrophic lateral sclerosis
  • Alzheimer's disease Parkinson's disease
  • Huntington's disease Huntington's disease
  • Guillain-Barre syndrome neuropathy
  • cognitive function decline associated with cardiopulmonary bypass surgery and related procedures.
  • Complement related inflammatory diseases or disorders include especially coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion, atherosclerosis, traumatic central nervous system injury, arrhythmogenic cardiomyopathy, bronchoconstriction, acute respiratory distress syndrome (ARDS), Chronic Obstructive Pulmonary Disorder (COPD), complement mediated thrombotic microangiopathies including atypical haemolytic uremic syndrome, and Gaucher disease.
  • Bullous diseases or disorders include especially bullous pemphigoid, bullous acquisita, pemphigus foliaceus, pemphigus vulgaris, sub-epidermal blisters, and hidradenitis suppurativa.
  • ischemic reperfusion injury including myocardial ischemia-reperfusion injury, and ischemic / reperfusion injury resulting from transplantation, including solid organ transplant
  • ischemic colitis ischemic colitis
  • cardiac ischemia especially myocardial ischemia-reperfusion injury, and ischemic / reperfusion injury resulting from transplantation, including solid organ transplant
  • Inflammatory bowel diseases or disorders include especially irritable bowel syndrome, ulcerative colitis, Crohn's disease, and inflammatory bowel disease (IBD).
  • IBD inflammatory bowel disease
  • Autoimmune diseases or disorders include especially rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus (SLE) and glomerulonephritis (GN, especially rapidly progressive GN) associated with lupus erythematosus (lupus nephritis), central nervous system (CNS) lupus, dermatomyositis, pemphigus, systemic sclerosis (scleroderma), autoimmune hemolytic and thrombocytopenic states, immunovasculitis, mixed cryoglobulinemia, atopic dermatitis, chronic urticaria, psoriasis, myasthenia gravis, and anti-phospholipid syndrome.
  • SLE systemic lupus erythematosus
  • GN glomerulonephritis
  • CNS central nervous system
  • lupus dermatomyositis
  • pemphigus pemphigus
  • inflammatory diseases or disorders associated with elevated levels of C5a and/or with C5aR activation include especially neutropenia, sepsis, septic shock, stroke, inflammation associated with severe burns, osteoarthritis, acute (adult) respiratory distress syndrome (ARDS), chronic pulmonary obstructive disorder (COPD), asthma, especially bronchial asthma, systemic inflammatory response syndrome (SIRS), tissue graft rejection, hyperacute rejection of transplanted organs, multiple organ dysfunction syndrome (MODS), diabetic retinopathy, neuromyelitis optica, and glomerulonephritis including Heyman nephritis / membranous glomerulonephritis, Berger's disease (IgA nephropathy), and other forms of glomerulonephritis such as C3 glomerulopathy including dense deposit disease.
  • neutropenia especially neutropenia, sepsis, septic shock, stroke, inflammation associated with severe burns, osteoarthritis, acute (adult) respiratory distress syndrome
  • cancer notably refers to skin cancer including melanoma including metastatic melanoma; lung cancer including non-small cell lung cancer; bladder cancer including urinary bladder cancer, urothelial cell carcinoma; renal carcinomas including renal cell carcinoma, metastatic renal cell carcinoma, metastatic renal clear cell carcinoma; gastro-intestinal cancers including colorectal cancer, metastatic colorectal cancer, familial adenomatous polyposis (FAP), oesophageal cancer, gastric cancer, gallbladder cancer, cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer such as pancreatic adenocarcinoma or pancreatic ductal carcinoma; endometrial cancer; ovarian cancer; cervical cancer; neuroblastoma; prostate cancer including castrate-resistant prostate cancer; brain tumors including brain metastases, malignant gliomas, glioblastoma multiforme, medulloblastoma, meningiomas; breast cancer including triple negative breast carcinoma; oral tumors
  • such use includes use of the present compounds as single therapeutic agents and their use in combination with one or more chemotherapy agents and / or radiotherapy and / or targeted therapy (especially in combination with targeted therapy).
  • radiotherapy or “radiation therapy” or “radiation oncology” refer to the medical use of ionizing radiation in the prevention / prophylaxis (adjuvant therapy) and / or treatment of cancer; including external and internal radiotherapy.
  • targeted therapy refers to the prevention / prophylaxis (adjuvant therapy) and / or treatment of cancer with one or more anti-neoplastic agents such as small molecules or antibodies which act on specific types of cancer cells or stromal cells.
  • Some targeted therapies block the action of certain enzymes, proteins, or other molecules involved in the growth and spread of cancer cells.
  • Other types of targeted therapies help the immune system kill cancer cells (immunotherapies); or inhibit angiogenesis, the growth and formation of new blood vessels in the tumor; or deliver toxic substances directly to cancer cells and kill them.
  • An example of a targeted therapy which is in particular suitable to be combined with the compounds of the present invention is immunotherapy, especially immunotherapy targeting the progammed cell death receptor 1 (PD-1 receptor) or its ligand PD-L1.
  • PD-1 receptor progammed cell death receptor 1
  • PD-L1 progammed cell death receptor 1
  • target therapy especially refers to agents such as:
  • immune checkpoint inhibitors When used in combination with the present compounds, immune checkpoint inhibitors, and especially those targeting the PD-1 receptor or its ligand PD-L1, are preferred.
  • the invention further relates to a compound of formula (I) for use in a method of modulating (especially downregulating) the consequences of the complement activation (especially by activating innate cells) in a subject in need thereof [especially in a subject having a disease or disorder related to pathogenic events associated with elevated levels of C5a and/or with C5aR activation; in particular in a subject having a vasculitic disease or disorder, an inflammatory disease or disorder involving intravascular microvesicle release, an immune complex (IC) disease or disorder, a neurodegenerative disease or disorder, a complement related inflammatory disease or disorder, a bullous disease or disorder, a disease or disorder related to ischemia and/or ischemic reperfusion injury, an inflammatory bowel disease or disorder, or an autoimmune disease or disorder; or in a subject having a contact sensitivity or an inflammation caused by contact with artificial surfaces; an increased leukocyte and platelet activation (and infiltration to tissues thereof); a pathologic sequelae associated to an intoxication or an injury such as
  • a further aspect of the invention is a process for the preparation of compounds of Formula (I) as defined in any one of embodiments 1) to 50).
  • Compounds of Formula (I) can be prepared from commercially available or well known starting materials according to the methods described in the experimental part, by analogous methods; or according to the general sequence of reactions outlined below, wherein R 1 , R A , R 2 , R 3 , R 4 , X, Y and Z are as defined for Formula (I).
  • Other abbreviations used herein are explicitly defined or are as defined in the experimental section.
  • the generic groups R 1 , R A , R 2 , R 3 , R 4 , X, Y and Z might be incompatible with the assembly illustrated in the schemes below and so will require the use of protecting groups (PG).
  • protecting groups is well known in the art (see for example " Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-Interscience, 1999 ). For the purposes of this discussion, it will be assumed that such protecting groups as necessary are in place.
  • the compounds obtained may also be converted into salts, especially pharmaceutically acceptable salts thereof in a manner known per se.
  • Compounds of structure A-1 can be prepared by reductive amination of suitable aldehydes of structure BB-4 with suitable amines of structure BB-7 using standard conditions such as treatment with NaBH(OAc) 3 in the optional presence of AcOH and a suitable solvent such as DCM, MeOH, THF or a mixture thereof at temperatures around RT.
  • NaBH 4 can be used as reducing agent in the presence of TFE as solvent according to Synthesis, 2011, 3, 490-496 .
  • a two-step procedure can be applied (i) condensation of a suitable aldehyde of structure BB-4 with amines of structure BB-7 in the presence of a suitable solvent such as MeOH at temperatures around 60°C and (ii) subsequent reduction of the intermediate imine by treatment with NaBH 4 at temperatures between 0°C and RT (Scheme A1, step a).
  • Diamino compounds of structure A-2 can be prepared by reduction of the nitro group in compounds of structure A-1 using standard conditions such as catalytic hydrogenation with a suitable catalyst such as Pd/C in a suitable solvent such as EtOAc or EtOH or a mixture thereof (Scheme A1, step b).
  • diamino compounds of structure A-2 can be prepared by reductive alkylation of a suitable amine of structure BB-5 with ketones of structure BB-8 using standard conditions such as treatment with NaBH(OAc) 3 in the optional presence of AcOH and a suitable solvent such as DCM, MeOH, THF or a mixture thereof at temperatures around RT.
  • Treatment of a suitable amine of structure BB-5 with tosylate of structure BB-33 in the presence of a suitable solvent such as MeCN at temperatures around 110°C under microwave irradiation can be an alternative procedure to provide diamino compounds of structure A-2 (Scheme A1, step c).
  • An alternative preparation of compounds of structure A-2 may be a reductive amination of a suitable aldehyde of structure BB-6 (or BB-20, respectively) with amines of structure BB-7 using standard conditions such as treatment with NaBH(OAc) 3 in the optional presence of AcOH (or with NaBH 4 , respectively) and in the presence of a suitable solvent such as DCM, MeOH, THF or a mixture thereof (or TFE, respectively) at temperatures around RT (or around 35°C, respectively) (Scheme A1, step d (or step g, respectively)).
  • a suitable solvent such as DCM, MeOH, THF or a mixture thereof (or TFE, respectively
  • Compounds of structure A-2 may alternatively be prepared by cleavage of the Boc protecting group in suitable compounds of structure A-4 (e.g. wherein R 5 represents (C 1-4 )alkyl, (C 2-3 )fluoroalkyl, or (C 3-6 )cycloalkyl-(C 0-4 )alkylene, or the like) using a suitable acid such as HCI or TFA in the presence of a suitable solvent such as dioxane, MeOH or DCM at temperatures around RT (Scheme A1, step f).
  • suitable acids such as HCI or TFA
  • a suitable solvent such as dioxane, MeOH or DCM
  • Cyclic ureas of structure A-3 can be prepared by cyclisation of diamines of structure A-2 by treatment with a suitable carbonyl transfer agent such as CDI in the presence of a suitable aprotic solvent such as MeCN or THF at temperatures between RT and 80°C (Scheme A1, step h).
  • a suitable carbonyl transfer agent such as CDI
  • a suitable aprotic solvent such as MeCN or THF
  • alkylation of the nitrogen atom having a free valency in compounds of structure A-3 can be achieved using Mitsunobu conditions by treatment with a suitable alcohol of structure BB-9 wherein W represents hydroxy and for instance a (cyanomethylene)trialkylphosphorane reagent in the presence of a suitable solvent such as toluene at temperatures around 110°C (Scheme A1, step i).
  • Compounds of structure Ib, Ic, Id, Ie, If and Ig can be prepared from suitable precursors of structure Ia according to the synthetic routes given in scheme A2 below, wherein said compounds of structure Ia may carry suitable protecting groups or functional groups as indicated.
  • Compounds of structure Ib wherein at least two of X, Y or Z represent N can be prepared from the corresponding N-SEM derivatives of compounds of structure Ia by cleavage of the SEM protecting group using for instance a suitable acid such as TFA in the presence of a suitable solvent such as DCM at temperatures around RT. An additional treatment with ethylenediamine in the presence of THF as solvent at temperatures around 60°C might be necessary to achieve complete cleavage of the SEM protecting group (Scheme A2, step a).
  • compounds of structure Ib wherein at least two of X, Y or Z represent N can be prepared from the corresponding Bn-protected derivatives by cleavage of the Bn protecting group in compounds of structure Ia by catalytic hydrogenation using a suitable catalyst such as Pd/C in the presence of a suitable solvent such as EtOH or MeOH and under a hydrogen atmosphere at temperatures around RT.
  • Catalytic transfer hydrogenation conditions using for instance ammonium formate can be an alternative procedure (Scheme A2, step a).
  • compounds of structure Ib wherein at least two of X, Y or Z represent N can be prepared from the corresponding THP-protected derivatives by cleavage of the THP protecting group in compounds of structure Ia by treatment with a suitable acid such as TFA in the presence of a suitable solvent such as DCM at temperatures around RT (Scheme A2, step a).
  • Compounds of structure Ic (or Id or Ie, respectively) wherein R 5 (or R 8 , respectively) represents methyl can be prepared by treatment with a methylating reagent such as Mel in the presence of a suitable base such as DBU and a suitable solvent such as DMF at temperatures around RT. Treatment with Mel in the presence of Ag 2 CO 3 as base and heating in a suitable solvent such as toluene at temperatures around 85°C can be an alternative procedure (Scheme A2, step b, c or d).
  • a methylating reagent such as Mel in the presence of a suitable base such as DBU and a suitable solvent such as DMF at temperatures around RT.
  • Treatment with Mel in the presence of Ag 2 CO 3 as base and heating in a suitable solvent such as toluene at temperatures around 85°C can be an alternative procedure (Scheme A2, step b, c or d).
  • a free NH group corresponding to X, Y or Z can be alkylated by treatment with a suitable halide, aziridine, epoxide or tosylate of structure BB-10 in the presence of a suitable base such as NaH, K 2 CO 3 or Cs 2 CO 3 and in solvents such as THF, DMF or DMA or a mixture thereof at temperatures between 0°C and 150°C under possible microwave irradiation can afford the corresponding compounds of structure Ic (Scheme A2, step b, c or d).
  • a suitable halide, aziridine, epoxide or tosylate of structure BB-10 in the presence of a suitable base such as NaH, K 2 CO 3 or Cs 2 CO 3 and in solvents such as THF, DMF or DMA or a mixture thereof at temperatures between 0°C and 150°C under possible microwave irradiation can afford the corresponding compounds of structure Ic (Scheme A2, step b, c or d).
  • Mitsunobu conditions can be used by treatment with a suitable alcohol of structure BB-10 and for instance with a (cyanomethylene)trialkylphosphorane reagent in the presence of a suitable solvent such as toluene at temperatures around 110°C (Scheme A2, step b,c or d).
  • a suitable solvent such as toluene at temperatures around 110°C (Scheme A2, step b,c or d).
  • Conditions for a 1,4-nucleophilic addition can alternatively be applied by treatment with a suitable ethyl or methyl 2-alkenoate or 2-nitroalkene of structure BB-10 in the presence of a suitable base such as CsF, TEA or K 2 CO 3 and a suitable solvent such as THF or DMF at temperatures between 0°C and 60°C (Scheme A2, step b,c or d).
  • a suitable base such as CsF, TEA or K 2 CO 3
  • a suitable solvent such as THF or DMF
  • alkoxycarbonylation (or alkylcarbamylation, respectively) can be performed by treatment with a suitable alkylchloroformate (or alkylisocyanate, respectively) of structure BB-10 in the presence of a suitable base such as TEA or DIPEA and a suitable solvent such as DCM or DMF at temperatures between 0°C and RT.
  • Di-alkylcarbamylation can be achieved by treatment with a suitable carbonyl transfer reagent such as CDI and a suitable amine of structure BB-10 in the presence of a suitable base such as TEA or DIPEA and a suitable solvent such as THF or DCM at temperatures around RT (Scheme A2, step b,c or d).
  • Chan-Lam conditions can be applied by treatment with a suitable boronic acid or boronic ester of structure BB-10 in the presence of a suitable copper catalyst such as Cu(OAc) 2 and a suitable ligand such as 2,2'-bipyridyl, in the presence of a suitable base such as Na 2 CO 3 and heating in a suitable solvent such as toluene or trifluoromethylbenzene at temperatures between 70°C and 90°C (Scheme A2, step b,c or d).
  • a suitable copper catalyst such as Cu(OAc) 2 and a suitable ligand such as 2,2'-bipyridyl
  • a suitable base such as Na 2 CO 3
  • a suitable solvent such as toluene or trifluoromethylbenzene at temperatures between 70°C and 90°C
  • compounds of structure If can be prepared from compounds of structure Ic (and sub-sequently compounds of structure Ig from compounds of structure If) by conventional functional group transformation, e.g. within the substituent R 5 , as described below (Scheme A2, step e; sub-sequently step f):
  • Reductive alkylation of amines of structure B-1 with aldehydes or ketones of structure BB-12 using standard conditions such as treatment with NaBH(OAc) 3 in the presence of AcOH (or NaBH 4 , respectively) and in the presence of a suitable solvent such as DCM, MeOH, THF or a mixture thereof (or TFE, respectively) at temperatures between RT and 40°C can afford compounds of structure B-2 (Scheme B, step b).
  • Cleavage of the Boc protecting group in compounds of structure B-2 wherein R 1 does not represents Boc can be performed by treatment with a suitable acid such as HCI or TFA in the presence of a suitable solvent such as dioxane, MeOH or DCM at temperatures around RT to afford diamines of structure B-3 (Scheme B, step c).
  • a suitable acid such as HCI or TFA
  • a suitable solvent such as dioxane, MeOH or DCM
  • Cyclic ureas of structure Ia can be prepared by cyclisation of compound of structure B-3 by treatment with a suitable carbonyl transfer agent such as CDI, DSC or phosgene in the presence of a suitable aprotic solvent such as MeCN at temperatures around 80°C (Scheme B, step d).
  • a suitable carbonyl transfer agent such as CDI, DSC or phosgene
  • a suitable aprotic solvent such as MeCN
  • Heteroaryl groups which are substituted by one fluorine atom in ortho position to a ring nitrogen atom can be prepared by aromatic nucleophilic substitution of CsF on the corresponding chloro heteroaryl group in the presence of a suitable solvent such as DMSO under possible microwave irradiation at temperatures around 100°C (Scheme B, step e).
  • Alkylated (hetero)aryl groups be prepared by Suzuki cross coupling of a suitable aromatic chloride with a (C 1 -C 4 )-alkyl boronic acid or boroxine in the presence of a suitable palladium catalyst such as Pd(dppf)Cl 2 .CH 2 Cl 2 or PEPPSI-IPr, in the presence of a suitable base such as K 2 CO 3 and heating in a suitable solvent such as dioxane at temperatures around 100°C (Scheme B, step e).
  • a suitable palladium catalyst such as Pd(dppf)Cl 2 .CH 2 Cl 2 or PEPPSI-IPr
  • Aromatic nucleophilic substitution of sodium alkoxides (or suitable amines) on suitable (hetero)aryl groups e.g. heteroaryl groups which are substituted by one chlorine atom in ortho position of a nitrogen, in the presence of the coresponding alcohol as solvent (or in the presence of a suitable solvent such as MeOH, respectively) at temperatures around 80°C (or at temperatures between 80°C and 150°C under microwave irradiation, respectively) may afford e.g.
  • R 2 represents a mono-, di- or tri-substituted 5- or 6-membered heteroaryl which is substituted by one (C 1-4 )alkoxy substituent (or R 21a R 21b N-) (Scheme B, step e).
  • Mitsunobu conditions can be used by treatment for instance with a (cyanomethylene)trialkylphosphorane reagent in the presence of a suitable solvent such as toluene at temperatures around 110°C (Scheme B, step e).
  • Compounds of structure C-1 can be prepared by reductive amination of suitable aldehydes of structure BB-14 (or ketones of structure BB-13, respectively) with suitable amines of structure BB-15 (or diamines of structure BB-5, respectively) using standard conditions as set out before.
  • NaBH 4 can be used as reducing agent in the presence of TFE as solvent at temperatures around 40°C according to Synthesis, 2011, 3, 490-496 (Scheme C, step b (or step a, respectively).
  • compounds of structure C-1 can be prepared by a two step procedure (i) reductive amination of suitable aldehydes of structure BB-4 with suitable amines of structure BB-15 using standard conditions as set out before and (ii) subsequent reduction of the nitro group in intermediates of structure C-4 using standard conditions such as catalytic hydrogenation with a suitable catalyst such as Pd/C in a suitable solvent such as EtOAc or EtOH or a mixture thereof (Scheme C, steps g and h).
  • Cyclic ureas of structure C-2 can be prepared by cyclisation of compound of structure C-1 by treatment with a suitable carbonyl transfer agent such as CDI in the presence of a suitable aprotic solvent such as MeCN at temperatures around RT (Scheme C, step c).
  • Boc protecting group in compounds of structure Ii can be as set out before to afford amines of structure C-3 (Scheme C, step e).
  • Compounds of structure Ij can be prepared by Buchwald-Hartwig cross coupling of halides of structure BB-16 wherein W represents iodine, bromine or chloride with amines of structure C-3 in the presence of a suitable palladium catalyst such as Pd 2 (dba) 3 and a suitable ligand such as BINAP, in the presence of a suitable base such as sodium tert-butoxide and heating in a suitable solvent such as toluene at temperatures between 100°C and 110°C (Scheme C, step f).
  • a suitable palladium catalyst such as Pd 2 (dba) 3
  • a suitable ligand such as BINAP
  • Aromatic nucleophilic substitution of amines of structure C-3 on suitable activated halogenides of structure BB-16 wherein W represents chlorine or fluorine in the presence of a suitable base such as K 2 CO 3 or CsF and heating in a suitable solvent such as DMSO under possible microwave irradiation at temperatures between 100°C and 130°C may alternatively afford compounds of structure Ij (Scheme C, step f).
  • Compounds of structure Ij can alternatively be prepared following a three-step procedure: (i) aromatic nucleophilic substitution of amines of structure C-3 on activated halides of structure BB-16 wherein W represents fluorine or chlorine which is substituted for instance by one formyl group in ortho position of the halogen atom W in the presence of a suitable base such as CsF or K 2 CO 3 and heating in a suitable solvent such as DMSO under microwave irradiation at temperatures between 60°C and 150°C and (ii) subsequent decarbonylation by treatment with a suitable acid such as toluene-4-sulfonic acid and in the presence of a suitable solvent such as MeOH under possible microwave irradiation at temperatures around 120°C and (iii) subsequent chlorination by treatment with a chlorinating reagent such as NCS in the presence of a suitable solvent such as THF at temperatures around RT (Scheme C, step f).
  • Compounds of structure D-1 can be prepared by reductive amination of suitable aldehydes of structure BB-19 with suitable amines of structure BB-7 using standard conditions as set out before (Scheme D, step a).
  • Heating compounds of structure D-1 in a suitable solvent such as DMF under microwave irradiation at temperatures around 120°C can alternatively afford compounds of structure A-3 (Scheme D, step b).
  • Compounds of structure E-1 can be prepared by reductive amination of suitable ketones of structure BB-26 (or BB-27, respectively) with suitable amines of structure BB-7 using standard conditions as set out before.
  • a two-step procedure can be applied (i) condensation of suitable ketones of structure BB-26 wherein R 4 represents (C 1-4 )alkyl with amines of structure BB-7 in the presence of titanium (IV) isopropoxide at temperatures around RT and (ii) subsequent reduction of the intermediate by treatment with NaBH 4 in the presence of a suitable solvent such as EtOH, THF or a mixture thereof at temperatures between -15°C and RT (Scheme E, step a (or step e, respectively)).
  • a suitable solvent such as EtOH, THF or a mixture thereof at temperatures between -15°C and RT
  • Compounds of structure E-4 can be prepared following a two-step procedure (i) condensation of suitable aldehydes or ketones of structure BB-12 with amines of structure BB-28 (or BB-34, respectively) in the presence of AcOH and a suitable solvent such as THF or MeOH at temperatures between RT and 60°C and (ii) subsequent reduction of the intermediate imine by treatment with NaBH 4 at temperatures between 0°C and RT (Scheme E, step f (or step j, respectively)).
  • compounds of structure E-5 can be prepared by Heck cross coupling of halides of structure E-7 (or E-8, respectively) with butyl vinyl ether or ethyl 1-propenyl ether in the presence of a suitable palladium catalyst such as Pd(OAc) 2 in combination with 1,3-bis(diphenylphosphino)propane or 2-(di-tert-butylphosphino)biphenyl as ligand, in the presence of a suitable base such as K 2 CO 3 and heating in a suitable solvent such as a mixture of DMF and H 2 O or MeCN at temperatures around 100°C.
  • a suitable base such as K 2 CO 3
  • a suitable solvent such as a mixture of DMF and H 2 O or MeCN at temperatures around 100°C.
  • the consecutive treatment with an acid such as HCI can release the ketone (Scheme E, step m (or step n, respectively).
  • Compounds of structure E-6 can be prepared following a two-step procedure (i) condensation of suitable ketones of structure E-5 (or E-10, respectively), e.g. wherein R 4 represents (C 1-4 )alkyl, with amines of structure BB-7 in the presence of titanium (IV) isopropoxide at temperatures around RT and (ii) subsequent reduction of the intermediate by treatment with NaBH 4 as set out before (Scheme E, step h (or step q, respectively)).
  • THP protecting group in compounds of structure E-5 wherein Y represents N-THP can be cleaved by treatment with a suitable acid such as TFA in the presence of a suitable solvent such as DCM at temperatures around RT to release compounds of structure E-9 wherein Y represents NH (Scheme E, step o).
  • Chan-Lam conditions can be applied to compounds of structure E-9 wherein Y represents NH by treatment with a suitable boronic acid or boronic ester of structure BB-10 in the presence of a suitable copper catalyst such as Cu(OAc) 2 and a suitable ligand such as 2,2'-bipyridyl, in the presence of a suitable base such as Na 2 CO 3 and heating in a suitable solvent such as toluene at temperatures between 70°C and 90°C (Scheme E, step p).
  • a suitable copper catalyst such as Cu(OAc) 2 and a suitable ligand such as 2,2'-bipyridyl
  • a suitable base such as Na 2 CO 3
  • a suitable solvent such as toluene at temperatures between 70°C and 90°C
  • aldehydes of structure BB-4 can be prepared according to scheme F below.
  • Esters of structure BB-1 wherein R e represents methyl (or ethyl, respectively) can be prepared by esterification of carboxylic acids of structure A by treatment with a strong acid such as H 2 SO 4 or HCI (which can be formed in situ from AcCl and MeOH (or EtOH, respectively)) and heating in a suitable alcohol such as MeOH (or EtOH, respectively) at temperatures around 80°C (Scheme F, step a).
  • a strong acid such as H 2 SO 4 or HCI (which can be formed in situ from AcCl and MeOH (or EtOH, respectively)
  • a suitable alcohol such as MeOH (or EtOH, respectively) at temperatures around 80°C (Scheme F, step a).
  • Reduction of carboxylic esters of structure BB-1 or BB-2 can be achieved for instance by treatment with a suitable reducing reagent such as NaBH 4 or CaBH 4 (formed in situ from NaBH 4 and CaCl 2 ) in the presence of a suitable solvent such as MeOH, EtOH or THF or a mixture thereof at temperatures between 0°C and RT to give alcohols of structure BB-3 (Scheme F, step c and d).
  • a suitable reducing reagent such as NaBH 4 or CaBH 4 (formed in situ from NaBH 4 and CaCl 2 ) in the presence of a suitable solvent such as MeOH, EtOH or THF or a mixture thereof at temperatures between 0°C and RT to give alcohols of structure BB-3 (Scheme F, step c and d).
  • Oxidation of primary alcohols of structure BB-3 by treatment with a suitable oxidizing reagent such as MnO 2 in the presence of a suitable solvent such as DCM at temperatures between RT and 45°C can afford aldehydes of structure BB-4 (Scheme F, step e).
  • aldehydes of structure BB-4 can be prepared by protection of building blocks of structure BB-11 wherein one of X, Y or Z represents NH with a suitable protecting group.
  • the treatment for instance with SEM-CI under standard conditions provides building blocks of structure BB-4 wherein one of X, Y or Z represents N-SEM (Scheme F, step f).
  • aldehydes of structure BB-19 can be prepared according to scheme G below.
  • Carbamates of structure BB-17 can be prepared by treatment of suitable amines of structure B (in case none of X, Y and Z represents NH) with methylchloroformate in the presence of a suitable base such as TEA or DIPEA, catalytic amounts of DMAP and in a suitable solvent such as MeCN, DCM or DMF at temperatures between 0°C and RT (Scheme G, step a).
  • a suitable base such as TEA or DIPEA
  • catalytic amounts of DMAP and in a suitable solvent such as MeCN, DCM or DMF at temperatures between 0°C and RT
  • Reduction of the ester function in building blocks of structure BB-17 can be achieved for instance by treatment with a suitable reducing reagent as set out before to give alcohols of structure BB-18 (Scheme G, step b).
  • Oxidation of primary alcohols of structure BB-18 by treatment with a suitable oxidizing reagent such as MnO 2 as set out before can afford aldehydes of structure BB-19 (Scheme G, step c).
  • aldehydes of structure BB-20 can be prepared according to scheme H below.
  • Aromatic nucleophilic substitution of sodium azide on suitable activated bromides of structure C in the presence of a suitable solvent such as DMSO at temperatures around RT can provide aldehydes of structure BB-20 (Scheme H, step a).
  • amines of structure BB-24 can be prepared according to scheme I below.
  • Building blocks of structure BB-21 can be prepared by treatment of amines of structure D wherein one of X, Y or Z represents NH and the two others represent N with Boc 2 O in the presence of a suitable base such as TEA or DIPEA in a suitable solvent such as THF or DCM at temperatures between 0°C and RT (Scheme I, step a). Alkylation of building blocks of structure BB-21 wherein one of X, Y or Z represents NH and the two others represent N with suitable halides of structure R 5 -W wherein W represents chlorine, bromine or iodine usinf conditions set out before may afford building blocks of structure BB-22 (Scheme I, step b).
  • amines of structure BB-7 and ketones of structure BB-8 can be prepared according to the synthetic routes given in scheme J below.
  • Building blocks of structure BB-29 can be prepared by standard Buchwald-Hartwig cross coupling of halides of structure R 1 -W wherein W represents iodine, bromine or chloride with amines of structure E (Scheme J, step a).
  • building blocks of structure BB-29 wherein can be prepared by standard aromatic nucleophilic substitution of amines of structure E on activated halides of structure R 1 -W wherein W represents fluorine or chlorine (Scheme J, step a). Cleavage of the ketal protecting group in building blocks of structure BB-29 by acidic hydrolysis in the presence of a suitable acid such as aq.
  • ketones of structure BB-8 (Scheme J, step b).
  • Building blocks of structure BB-30 can be prepared by standard aromatic nucleophilic substitution of amines of structure F on activated halides of structure R 1 -W wherein W represents fluorine or chlorine (Scheme J, step c).
  • building blocks of structure BB-30 wherein R 1 represents a mono-, di- or tri-substituted phenyl which is substituted by one methyl group at the ortho position to the connecting nitrogen can be prepared following a four-step procedure: (i) aromatic nucleophilic substitution of amines of structure F on halides of structure R 1 -W wherein W represents fluorine or chlorine and R 1 represents a suitable mono-, or di-substituted phenyl which is substituted by one formyl group at the ortho position of the halogen atom W in the presence of a suitable base such as K 2 CO 3 and heating in a suitable solvent such as DMSO at temperatures between 100°C and 120°C and (ii) subsequent reduction of the benzaldehyde derivative by treatment with a suitable reducing reagent such as NaBH 4 in the presence of a suitable solvent such as MeOH at temperatures between 0°C and RT and (iii) subsequent acetylation of the resulting benzyl alcohol by
  • building blocks of structure BB-30 wherein R 1 represents a mono- or di-substituted phenyl or pyridine which is substituted by one difluoromethyl group at the ortho position to the connecting nitrogen can be prepared following a two-step procedure: (i) aromatic nucleophilic substitution of amines of structure F on halides of structure R 1 -W wherein W represents fluorine or chlorine and R 1 represents a suitable mono-, or di-substituted phenyl or pyridine which is substituted by one formyl group at the ortho position of the halogen atom W as set out before and (ii) subsequent difluorination of the benzaldehyde derivative by treatment with a suitable fluorinating reagent such as bis(2-methoxyethyl)aminosulfur trifluoride in the presence of a suitable solvent such as DCM at temperatures around RT (Scheme J, step c).An alternative sequence of reactions can provide compounds of structure BB-30 wherein R 1 represents a
  • a three-step procedure is followed (i) aromatic nucleophilic substitution of amines of structure F on halides of structure R 1 -W wherein W represents fluorine or chlorine and R 1 represents a suitable mono-, or di-substituted phenyl which is substituted by one nitro group at the ortho position of the halogen atom W as set out before and (ii) subsequent reduction of the nitro group to an amino group as set out before and (iii) subsequent Sandmeyer rxn to introduce a halogen atom using standard conditions.
  • An additional Suzuki or Kumada cross coupling reaction can be used to introduce an (C 1-4 )alkyl or (C 3-6 )cycloalkyl group at the place of the halogen atom(Scheme J, step c).
  • Transformation of ketones of structure BB-8 to amines of structure BB-7 can be achieved by reductive amination with for instance aq. ammonia under catalytic hydrogenation conditions using a suitable catalyst such as Pd/C in the presence of a suitable solvent such as dioxane at temperatures around RT (Scheme J, step e).
  • the enantiomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-O1 (R,R) (10 ⁇ m) column, a Daicel ChiralCel OD-H (5-10 ⁇ m) column, or a Daicel ChiralPak IA (10 ⁇ m), IC (5 ⁇ m) or AD-H (5 ⁇ m) column.
  • a chiral stationary phase such as a Regis Whelk-O1 (R,R) (10 ⁇ m) column, a Daicel ChiralCel OD-H (5-10 ⁇ m) column, or a Daicel ChiralPak IA (10 ⁇ m), IC (5 ⁇ m) or AD-H (5 ⁇ m) column.
  • a chiral stationary phase such as a Regis Whelk-O1 (R,R) (10 ⁇ m) column,
  • LC-MS (Method I): Waters Acquity UPLC i-Class system with Waters i-Class BSM binary pump, Thermo MSQ Plus MS detector and Waters Acquity PDA detector.
  • LC-MS (Method II): Dionex Ultimate 3000 system with Dionex HPG-3200RS binary pump, Thermo MSQ Plus MS detector and Dionex DAD-3000RS PDA detector.
  • LC-MS (Method III): Dionex Ultimate 3000 system with Dionex HPG-3200SD binary pump, Thermo MSQ Plus MS detector and Dionex DAD-3000RS PDA detector.
  • LC-MS (Method IV): Waters Acquity UPLC i-Class system with Waters i-Class BSM binary pump, Thermo MSQ Plus MS detector and Waters Acquity PDA detector.
  • Bruker Avance HD spectrometer equipped with a 500 MHz Ultrashield TM Magnet and a 5 mm DCH cryoprobe or Bruker Avance II spectrometer equipped with a 400 MHz Ultrashield TM Magnet and a BBO 5mm probehead.
  • Chemical shifts ( ⁇ ) are reported in parts per million (ppm) relative to proton resonances resulting from incomplete deuteration of the NMR solvent, e.g. for dimethylsulfoxide ⁇ (H) 2.49 ppm, for chloroform ⁇ (H) 7.24 ppm.
  • the abbreviations s, d, t, q and m refer to singlet, doublet, triplet, quartet, multiplet, respectively and br to broad.
  • Coupling constants J are reported in Hz.
  • the compounds were purified by either column chromatography on silica-gel and/or prep. LC-MS using the conditions described below.
  • Gilson 333/334 Prep-Scale HPLC pump equipped with Gilson LH215 autosampler, Dionex SRD-3200 degasser, Dionex ISO-3100A make-up pump, Dionex DAD-3000 DAD detector and Thermo MSQ Plus Single Quadrupole MS detector. Flow: 75 mL/min. Detection: UV/Vis and/or MS.
  • the building blocks are prepared according to the procedures described below.
  • Step A Cyclocondensation (see Table 5)
  • Step B Nitrile reduction (see Table 6)
  • Nitrile BB-5A (1 eq) was dissolved in a 7M soln. of NH 3 in MeOH (7 mL/mmol). The flask was evacuated three times and refilled with nitrogen. Raney nickel (0.1 eq) was added at 0°C and the temperature was allowed to reach RT. The flask was evacuated and refilled three times with hydrogen. The suspension was stirred under a hydrogen atmosphere for 11h and filtered over a pad of Celite. The cake was washed with EtOAc and MeOH and the filtrate was concentrated in vacuo.
  • BB-7 Name Reactant BB-30 or BB-8 Method t R [min] (LC/MS method) MS-data m/z [M+H] + BB-7-1 1-(2-Fluoro-6-methyl-phenyl)-piperidin-4-ylamine BB-30-1 A 0.62 (I) 209.21 BB-7-2 2'-Methoxy-4'-methyl-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-4-ylamine BB-8-2 B 0.51 (I) 222.27 BB-7-3 1-(2-Fluoro-6-methyl-phenyl)-4-methyl-piperidin-4-ylamine BB-30-2 A 0.65 (I) 223.19 BB-7-4 1-(2-Fluoro-6-methyl-phenyl)-3-methyl-pyrrolidin-3-ylamine BB-30-3 A 0.65 (I) 209.28 BB-7-5 (R)-1-(2-Fluoro-6-methylphenyl
  • Step B1 O-Alkylation via Mitsunobu (see Table 10)
  • Step B2 Methyl / ethyl ester reduction using CaCl 2 / MaBH 4 (see Table 13)
  • Step B3 Methyl / ethyl ester reduction using LiAlH 4 (see Table 13)
  • Step C1 nucleophilic aromatic substitution (see Table 11)
  • Step C2 hydrogenation (see Table 12)
  • ester intermediate BB-9B (1 eq) in anh. EtOH (15.8 mL/mmol) was added CaCl 2 (0.3 eq) and the rxn mixture was cooled to -10°C. NaBH 4 (2.5 eq) was added portionwise and the mixture was stirred for 30 min at -10°C and for 3.5h at RT. It was quenched at 0°C with water and EtOH was evaporated off. The residue was partitioned between EtOAc and water and the aq. phase was further extracted with EtOAc. The combined org. phases were washed with brine, dried over MgSO 4 and concentrated in vacuo.
  • Step A Carboxylic acid reduction (see Table 14)
  • Step B Appel rxn (see Table 15)
  • Step B aziridine formation (see Table 15)
  • a 2.4 M soln. of LiAlH 4 in THF (1 eq) was diluted with anh. THF (2 mL/mmol) and cooled to -10°C.
  • a soln. of ethyl ester BB-17 (1 eq, see Table 19) in anh. THF (2 mL/mmol) was added dropwise at -10°C.
  • the rxn mixture was allowed to warm from -10°C to 5°C over 1h and quenched successively at 0°C with ice water, with a 2M aq. soln. of NaOH and with ice water.
  • the suspension was diluted with THF, stirred for 30 min at RT, filtered over a pad of celite and the filtrate was concentrated in vacuo.
  • Nitrile BB-23 (1 eq) was dissolved in a 7M soln. of NH 3 in MeOH (7 mL/mmol). The flask was evacuated and refilled with nitrogen. Raney nickel (0.1 eq) was added at 0°C and the temperature was allowed to reach RT. The flask was evacuated and refilled with hydrogen. The suspension was stirred under a hydrogen atmosphere at RT for 4h (see Table 24) and filtered over a pad of Celite. The cake was washed with MeOH and the filtrate was concentrated in vacuo.
  • BB-26 Name Method Reactant ketone t R [min] (LC/MS method) MS-data m/z [M+H] + 1 H NMR (500 MHz, DMSO-d6) ⁇ : BB-26-1 1-(1-Methyl-4-nitro-1H-pyrazol-3-yl)-ethanone commercially available BB-26-2 1 -[4-N itro-2-(2-trimethylsilanyl-ethoxymethyl)-2H-pyrazol-3-yl]-ethanone A 1-(4-Nitro-1H-pyrazol-5-yl)ethanone 1.05 (I) no io 8.41 (s, 1 H), 5.48 (s, 2 H), 3.55 (m, 2 H), 2.65 (s, 3 H), 0.85 (m, 2 H), -0.03 (m, 9 H) BB-26-3 1-[4-Nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazol-3-
  • BB-29 Name Reactant amine E Reactant halide T[°C] time [h] t R [min] (LC/MS method) MS-data m/z [M+H] + BB-29-1 8-(2-Fluoro-6-methylphenyl)-1,4-dioxa-8-aza-spiro[4.5]decane 1,4-Dioxa-8-azaspiro[4.5]d ecane 2-Bromo-3-fluorotoluene 100 18 1.01 (I) 252.19 BB-29-2 8-(2-Methoxy-4-methyl-pyridin-3-yl)-1,4-dioxa-8-aza-spiro[4.5]decane 1,4-Dioxa-8-azaspiro[4.5]d ecane 3-Bromo-2-methoxy-4-methyl pyridine 100 20 0.81 (I) 265.19 BB-29-3 8-(2-Fluoro-6-methylphenyl
  • Step A Aromatic nucleophilic substitution
  • Step B
  • Method A hydrogenation (using BB-30C) Intermediate BB-30C (1 eq) was dissolved in a mixture of MeOH (6 mL/mmol) and EtOAc (2 mL/mmol) and the flask was evacuated three times and refilled with nitrogen (see Table 32). Wet Pd/C (0.08 eq) was added and the flask was evacuated three times and refilled with hydrogen. The suspension was hydrogenated under atmospheric pressure for 3h and filtered over a pad of Celite. The cake was washed with EtOAc and MeOH and the filtrate was concentrated in vacuo. The crude was purified by CC using Hept/EtOAc.
  • the rxn mixture was added dropwise at 0°C to a suspension of copper(I) chloride (1.5 eq) and copper(II) chloride (3 eq) in H 2 O (3.1 mL/mmol).
  • the resulting soln. was stirred for 18h allowing the temperature to reach RT. It was partitionned between EtOAc and a sat. soln. of NH 4 Cl.
  • the org. phase was washed with a sat. soln. of NH 4 Cl and brine, dried over MgSO 4 and concentrated in vacuo.
  • the crude was purified by CC using Hept/EtOAc.
  • the org. phase was washed with H 2 O and brine, dried over MgSO 4 and concentrated in vacuo.
  • the crude was purified by CC using Hept/EtOAc and when necessary, an additional purification by prep. LC-MS using method 1 was performed.
  • BB-34 Name BB-34-1 3-amino-4-bromopyrazole commercially available BB-34-2 4-Bromo-1-methyl-1H-pyrazol-3-ylamine
  • Step B (additional treatment):
  • the crude was dissolved in THF (5 to 10 mL/mmol) and treated with ethylenediamine (3 eq) for 30 min to 1h at 60°C.
  • the rxn mixture was partitioned between DCM and water and the org. phase was washed with brine, dried over MgSO 4 and concentrated in vacuo.
  • the crude was purified by CC using Hept/EtOAc.
  • Step B treatment with alcohol
  • the crude was dissolved in EtOH or MeOH (5 mL/mmol) and treated with a 4M soln. of HCI in dioxane (5 mL/mmol) for 30 min at 70°C.
  • the rxn mixture was basified with a 1M aq. soln. of NaOH until pH 8-9 and extracted with DCM.
  • Method B1 A soln. or suspension of intermediate Ib (1 eq) in anh. THF (6 to 10 mL/mmol) was added dropwise at 0°C to a suspension of NaH (2.2 to 4 eq, as a 60% dispersion in mineral oil) in anh. THF (4 to 6 mL/mmol).
  • Method B2 NaH (4 eq, as a 60% dispersion in mineral oil) was added portionwise at 0°C to a soln. or suspension of intermediate Ib (1 eq) in THF (10 to 13 mL/mmol).
  • H RT 1 1.27 (I) 574.10 Ic-36 5-[1-(2-Fluoro-6-methyl-phenyl)-piperidin-4-yl]-6-oxo-7-(2-trifluoromethyl-benzyl)-4,5,6,7-tetrahydro-pyrazolo[3,4-d]pyrimidine-2-carboxylic acid isobutyl ester (Example 148) Ib-2 Isobutyl chloroform ate H RT 1.5 1.30 (I) 588.12 Ic-37 5-[1-(2-Fluoro-6-methyl-phenyl)-piperidin-4-yl]-6-oxo-7-(2-trifluoromethyl-benzyl)-4,5,6,7-tetrahydro-pyrazolo[3,4-d]pyrimidine-2-carboxylic acid dimethylamide (Example 149) Ib-2 Dimethylamine (2M soln.
  • Step A Acetal cleavage
  • Step A Acetal cleavage
  • Step B Reductive amination
  • Step B phtalimide cleavage
  • Step A Aromatic nucleophilic susbtitution
  • Racemates of formula la, Ic or Ij were separated into the respective enantiomers using preparative chiral HPLC or SFC (equipped with a given column and eluting with given parameters (see Table 69), detection: UV 210 nm).
  • the absolute configuration for the molecule Ik-70 (Example 324, enantiomer B) was assessed by single crystal X-ray diffraction (suitable crystal obtained from iPrOH) and proved to be in absolute (R)-configuration. Consequently, the absolute configuration for the molecule Ik-69 (Example 323, enantiomer A) was assigned (S). In analogy, for all example compounds wherein R 4 represents methyl listed in Table 69 below, the enantiomer showing higher activity in the in vitro biological assay disclosed below may be assumed to have the absolute (S)-configuration.
  • Adherent cells (CHO-K1 C5AR1 beta-arrestin cell line, DiscoverX, CA USA) are washed with PBS, detached by incubation with Dissociation Buffer (Gibco Cat# 13151-014, 2 ml per 165 cm2 dish) for 3 minutes, then washed with 10 ml PBS (without Mg++ and Ca++) and counted. 7'500 cells/384-well are seeded out in 384-well plates (Cell culture plate MTP384 white Polystyrene, Corning, Cat# 3570) in 20 ⁇ l/well Cell plating medium (F12 HAMs/10% FCS/1% P/S) and incubated at 37°C / 5% CO2 / 24h.
  • Dissociation Buffer Gibco Cat# 13151-014, 2 ml per 165 cm2 dish
  • the calculated IC 50 values may fluctuate depending on the daily cellular assay performance. Fluctuations of this kind are known to those skilled in the art. Average IC 50 values from several measurements are given as geometric mean values.
  • Antagonistic activities of exemplified compounds are displayed in Table 70.
  • Table 70 list of examples and their antagonistic activities
  • Example Number Compound N° C5aR IC 50 (nM) Example Number Compound N° C5aR IC 50 (nM)
  • Example Number Compound N° C5aR IC 50 (nM) 1 la-1A 85 130 If-31 390 259 la-42 49 2 lb-1 10 131 lg-25 100 260 la-43 40 3 lc-2 36 132 lg-26 8 261 lk-25 580 4 ld-1 293 133 lg-27 22 262 lk-26 472 5 la-2 16 134 lg-28 13 263 lk-27 21 6 lb-2 9 135 lg-29 17 264 la-45 216 7 lc-1 16 136 lg-30 163 265 lk-29 12 8 lc-3 14 137 lg-31 81 266 lk-30 356 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
EP19700269.4A 2018-01-10 2019-01-09 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases Active EP3737684B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI201930400T SI3737684T1 (sl) 2018-01-10 2019-01-09 Derivati 2,4,6,7-tetrahidro-pirazolo(4,3-D)pirimidin-5-ona in sorodne spojine kot modulatorji receptorja C5A za zdravljenje vaskulitisa in vnetnih bolezni
HRP20221449TT HRP20221449T1 (hr) 2018-01-10 2019-01-09 Derivati 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona i pripadajući spojevi kao modulatori c5a receptora za liječenje vaskulitisa i upalnih bolesti
RS20221138A RS63806B1 (sr) 2018-01-10 2019-01-09 Derivati 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona i srodna jedinjenja kao modulatori c5a receptora za lečenje vaskulitisa i inflamatornih bolesti

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018050598 2018-01-10
PCT/EP2019/050372 WO2019137927A1 (en) 2018-01-10 2019-01-09 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases

Publications (2)

Publication Number Publication Date
EP3737684A1 EP3737684A1 (en) 2020-11-18
EP3737684B1 true EP3737684B1 (en) 2022-11-16

Family

ID=65012016

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19700269.4A Active EP3737684B1 (en) 2018-01-10 2019-01-09 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases

Country Status (29)

Country Link
US (2) US11608341B2 (uk)
EP (1) EP3737684B1 (uk)
JP (1) JP7014914B2 (uk)
KR (1) KR102574564B1 (uk)
CN (1) CN111566109B (uk)
AR (1) AR114564A1 (uk)
AU (1) AU2019207666B2 (uk)
BR (1) BR112020013788A2 (uk)
CA (1) CA3086310C (uk)
CL (1) CL2020001817A1 (uk)
DK (1) DK3737684T3 (uk)
EA (1) EA202091641A1 (uk)
ES (1) ES2933820T3 (uk)
HR (1) HRP20221449T1 (uk)
HU (1) HUE060515T2 (uk)
IL (1) IL275868B2 (uk)
LT (1) LT3737684T (uk)
MA (1) MA51558B1 (uk)
MX (1) MX2020007443A (uk)
PH (1) PH12020500583A1 (uk)
PL (1) PL3737684T3 (uk)
PT (1) PT3737684T (uk)
RS (1) RS63806B1 (uk)
SG (1) SG11202006490YA (uk)
SI (1) SI3737684T1 (uk)
TW (1) TWI774905B (uk)
UA (1) UA124694C2 (uk)
WO (1) WO2019137927A1 (uk)
ZA (1) ZA202004910B (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091641A1 (ru) * 2018-01-10 2020-11-17 Идорсия Фармасьютиклз Лтд 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5a ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
WO2019141808A1 (en) * 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US11739070B2 (en) 2018-01-19 2023-08-29 Idorsia Pharmaceuticals Ltd. C5A receptor modulators
CN114096252A (zh) * 2019-07-09 2022-02-25 爱杜西亚药品有限公司 包含四氢异喹啉化合物的药物组合物
US11193891B2 (en) * 2019-12-20 2021-12-07 Robert Bosch Gmbh Receptors and spacers for a fluorescence-based lead ion chemosensor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487798A4 (en) * 2002-03-28 2005-07-13 Neurogen Corp Substituted tetrahydroisoquinolines as C5A receptor modulators
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
PL2585064T3 (pl) * 2010-06-24 2017-09-29 Chemocentryx, Inc. Antagoniści C5AR
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
TWI736135B (zh) * 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2015034820A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
MX365218B (es) 2013-09-06 2019-05-27 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores.
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
CN106715431A (zh) * 2014-09-16 2017-05-24 吉利德科学公司 Toll样受体调节剂的固体形式
WO2017034872A1 (en) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Indazole derivatives useful as cb-1 inverse agonists
EA202091641A1 (ru) * 2018-01-10 2020-11-17 Идорсия Фармасьютиклз Лтд 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5a ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
WO2019141808A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US11739070B2 (en) 2018-01-19 2023-08-29 Idorsia Pharmaceuticals Ltd. C5A receptor modulators
CN114096252A (zh) 2019-07-09 2022-02-25 爱杜西亚药品有限公司 包含四氢异喹啉化合物的药物组合物

Also Published As

Publication number Publication date
PT3737684T (pt) 2022-12-20
JP7014914B2 (ja) 2022-02-01
BR112020013788A2 (pt) 2020-12-01
CA3086310A1 (en) 2019-07-18
MA51558A (fr) 2021-04-14
WO2019137927A1 (en) 2019-07-18
HUE060515T2 (hu) 2023-03-28
CN111566109B (zh) 2023-07-11
LT3737684T (lt) 2022-12-27
US20230192708A1 (en) 2023-06-22
AU2019207666A1 (en) 2020-08-27
IL275868A (en) 2020-08-31
ZA202004910B (en) 2024-02-28
IL275868B2 (en) 2023-06-01
ES2933820T3 (es) 2023-02-14
SG11202006490YA (en) 2020-08-28
CL2020001817A1 (es) 2020-12-04
TW201930307A (zh) 2019-08-01
EA202091641A1 (ru) 2020-11-17
UA124694C2 (uk) 2021-10-27
PH12020500583A1 (en) 2021-06-14
AU2019207666B2 (en) 2023-12-21
US20200369672A1 (en) 2020-11-26
US11608341B2 (en) 2023-03-21
KR102574564B1 (ko) 2023-09-04
DK3737684T3 (da) 2022-12-12
HRP20221449T1 (hr) 2023-01-20
MX2020007443A (es) 2020-09-14
JP2021510373A (ja) 2021-04-22
EP3737684A1 (en) 2020-11-18
AR114564A1 (es) 2020-09-23
RS63806B1 (sr) 2023-01-31
MA51558B1 (fr) 2022-12-30
KR20200106061A (ko) 2020-09-10
SI3737684T1 (sl) 2023-01-31
TWI774905B (zh) 2022-08-21
CN111566109A (zh) 2020-08-21
PL3737684T3 (pl) 2023-02-27
CA3086310C (en) 2023-09-19
TW202244047A (zh) 2022-11-16

Similar Documents

Publication Publication Date Title
EP3737684B1 (en) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases
AU2015328553C1 (en) Aminopyridyloxypyrazole compounds
US11739070B2 (en) C5A receptor modulators
ES2954152T3 (es) Moduladores del receptor de piperidina CXCR7
CA2847540A1 (en) Pyrrolopyrimidine and purine derivatives
US11091460B2 (en) Syk inhibitor and use method therefor
US11685729B2 (en) C5a receptor modulators
TWI839788B (zh) C5a受體調節劑
US20230126352A1 (en) Macrocyclic rip2-kinase inhibitors
EA042931B1 (ru) 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5A ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20221449T

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20200810

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210908

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20220531

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019021954

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20221208

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1531731

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221215

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3737684

Country of ref document: PT

Date of ref document: 20221220

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20221214

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 51558

Country of ref document: MA

Kind code of ref document: B1

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20221449

Country of ref document: HR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20221116

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20221449

Country of ref document: HR

Payment date: 20230103

Year of fee payment: 5

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220402455

Country of ref document: GR

Effective date: 20230110

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 40897

Country of ref document: SK

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2933820

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20230214

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E022954

Country of ref document: EE

Effective date: 20221215

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E060515

Country of ref document: HU

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20230123

Year of fee payment: 5

Ref country code: FR

Payment date: 20230124

Year of fee payment: 5

Ref country code: DK

Payment date: 20230123

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230203

Year of fee payment: 5

Ref country code: SE

Payment date: 20230119

Year of fee payment: 5

Ref country code: LV

Payment date: 20230115

Year of fee payment: 5

Ref country code: IT

Payment date: 20230228

Year of fee payment: 5

Ref country code: BE

Payment date: 20230119

Year of fee payment: 5

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230427

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221116

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019021954

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221116

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1531731

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221116

26N No opposition filed

Effective date: 20230817

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602019021954

Country of ref document: DE

Representative=s name: KRAUS & LEDERER PARTGMBB, DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20221449

Country of ref document: HR

Payment date: 20231228

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20231229

Year of fee payment: 6

Ref country code: RO

Payment date: 20231228

Year of fee payment: 6

Ref country code: PT

Payment date: 20231221

Year of fee payment: 6

Ref country code: MT

Payment date: 20231222

Year of fee payment: 6

Ref country code: LT

Payment date: 20231222

Year of fee payment: 6

Ref country code: HR

Payment date: 20231228

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231228

Year of fee payment: 6

Ref country code: NL

Payment date: 20240119

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240119

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240122

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240110

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240227

Year of fee payment: 6

Ref country code: IE

Payment date: 20240119

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240122

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240123

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240123

Year of fee payment: 6

Ref country code: FI

Payment date: 20240119

Year of fee payment: 6

Ref country code: EE

Payment date: 20240116

Year of fee payment: 6

Ref country code: DE

Payment date: 20240119

Year of fee payment: 6

Ref country code: CZ

Payment date: 20231229

Year of fee payment: 6

Ref country code: CY

Payment date: 20231222

Year of fee payment: 6

Ref country code: BG

Payment date: 20240122

Year of fee payment: 6

Ref country code: SK

Payment date: 20240104

Year of fee payment: 6

Ref country code: CH

Payment date: 20240202

Year of fee payment: 6

Ref country code: GB

Payment date: 20240123

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20231228

Year of fee payment: 6